Monoclonal antibodies in the prophylaxis and treatment of COVID-19 have been crucial in
reducing severe infections when vaccines were unavailable. However, as the virus and its …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

The global pandemic of COVID-19 is currently ongoing [1]. To date, pharmacological agents
used to treat patients with COVID-19 have been directed at avoiding and reducing the …

Monoclonal antibodies are a promising treatment for COVID-19. However, the emergence of
SARS-CoV-2 variants raised concerns about these therapies' efficacy and long-term …

With the number of Coronavirus Disease 2019 (COVID-19) cases soaring worldwide and
limited vaccine availability for the general population in most countries, the monoclonal …

The world is facing up the most considerable vaccination effort in history to end the
Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) …

Background We systematically assessed beneficial and harmful effects of monoclonal
antibodies for coronavirus disease 2019 (COVID-19) treatment, and prophylaxis in …

Coronavirus disease 2019 has generated a rapidly evolving field of research, with the global
scientific community striving for solutions to the current pandemic. Characterizing humoral …

Monoclonal antibodies (mAbs) have been known since the 1970s. However, their
therapeutic potential in the medical field has recently emerged, with the advancement of …

The COVID-19 pandemic continues to cause tremendous loss of life and put massive strain
on the functioning of societies worldwide. Despite the cataclysmic proportions of this viral …